Results 181 to 190 of about 17,579 (227)

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants. [PDF]

Clin Pharmacol Drug Dev
Zhou XJ, Morelli G, Montrond M, Lynch S, Pietropaolo K, Belanger B, Horga A, Hammond J.   +7 more
europepmc   +1 more source

Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy. [PDF]

Pathogens
Ke PY, Yeh CT.
europepmc   +1 more source

The architecture of membrane structures involved in hepatitis C virus genome replication revealed in close-to-native conditions by cryo-electron tomography

Sykora UM, O’ Sullivan TJ, Halfon Y, Fontana J, Harris M.   +4 more
europepmc   +1 more source

2025 KASL clinical practice guidelines for management of hepatitis C. [PDF]

Clin Mol Hepatol
Jang ES, Heo NY, Jeong JY, Park JG, Song DS, Cho EJ, Lee CH, Lee JS, Yoon JH, Han SK, Jung YK, Korean Association for the Study of the Liver (KASL).   +11 more
europepmc   +1 more source

Using Organs from Hepatitis C-Infected Donors: A Cautionary Experience. [PDF]

Transplant Direct
Shanahan E, Yoshida EM, Chartier-Plante S, Hussaini T.   +3 more
europepmc   +1 more source

Characterizations of HCV NS5A replication complex inhibitors

Virology, 2013
The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral intervention by small molecules. Characterizations are presented of compounds identified as potent inhibitors of HCV replication to provide insight into structural elements that interact with the NS5A protein.
Jin-hua Sun, Huan Wang, Nicholas A Meanwell   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

NS5A Inhibitors

Current Hepatitis Reports, 2012
As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The
Christopher O’Brien, Nicholas Agresti
openaire   +1 more source

HCV NS5A replication complex inhibitors

Current Opinion in Pharmacology, 2016
The development of anti-HCV drugs is one of the most successful stories of antiviral therapy. In fact, for the first time in human history we have the potential to eradicate a chronic viral infection using only orally administered direct antiviral agents (DAAs).
Min, Gao, Donald R, O'Boyle, Susan, Roberts   +2 more
openaire   +2 more sources

Discovery of fluorobenzimidazole HCV NS5A inhibitors

Bioorganic & Medicinal Chemistry Letters, 2016
Research toward a next-generation HCV NS5A inhibitor has identified fluorobenzimidazole analogs that demonstrate potent, broad-genotype in vitro activity against HCV genotypes 1-6 replicons as well as HCV NS5A variants that are orders of magnitude less susceptible to inhibition by first-generation NS5A inhibitors in comparison to wild-type replicons ...
John T, Randolph, Charles A, Flentge, Pamela, Donner, Todd W, Rockway, Sachin V, Patel, Lissa, Nelson, Douglas K, Hutchinson, Rubina, Mondal, Neeta, Mistry, Thomas, Reisch, Tatyana, Dekhtyar, Preethi, Krishnan, Tami, Pilot-Matias, Deanne F, Stolarik, David W A, Beno, Rolf, Wagner, Clarence, Maring, Warren M, Kati   +17 more
openaire   +2 more sources